Abstract: The present invention concerns compounds of the formula: ##STR1## where R.sub.1 is an alkyl or alkenyl radical containing up to 6 carbon atoms, a cycloalkyl radical containing 3 to 7 carbon atoms, an aralkyl, aralkenyl or aryl radical in which the aryl radical or moiety can be substituted one or more times by halogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxyl, trifluoromethyl, cyano, nitro, amino, C.sub.1 -C.sub.6 -alkylamino, C.sub.2 -C.sub.12 -dialkylamino, C.sub.1 -C.sub.6 -acylamino, C.sub.1 -C.sub.16 -acyl, C.sub.1 -C.sub.6 -alkylsulphenyl, -sulphinyl or -sulphonyl or by azido, R.sub.2 is hydrogen atom or a C.sub.1 -C.sub.6 -alkyl, aralkyl, aralkenyl or acyl radical, A and B are saturated or unsaturated alkylene chains containing up to 10 carbon atoms which can be substituted one or more times by C.sub.1 -C.sub.

Abstract: Substituted 1-arylpyrazoles useful in combating insects having the arachnida and nematodes of the formula ##STR1## in which R.sup.1 represents hydrogen or alkyl,R.sup.2 represents alkyl or halogenoalkyl,R.sup.3 represents hydrogen or alkanoyl,R.sup.4 represents hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, halogenoalkyl, alkenyl, halogenoalkenyl or alkinyl, in each case optionally substituted cycloalkyl, aralkyl or aryl, or, when X represents oxygen or sulphur, R.sup.4 can represent a cation equivalent which is bonded in a salt-like manner,A represents a double-linked alkylene radical,X represents oxygen, sulphur or a radical ##STR2## Ar represents optionally substituted phenyl, pyridyl and n represents a number 0, 1 or 2, where R.sup.5 represents hydrogen, alkyl, hydroxylalkyl, alkoxyalkyl, alylthioalkyl, halogenoalkyl, alkenyl, halogenoalkenyl or alkinyl, or represents optionally substituted cycloalkyl, aralkyl or aryl.

Abstract: Cycloalkano[1,2-b]indole-sulphonamides of the formula ##STR1## where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antoganize thromboxane A.sub.2.

Abstract: Tinnitus symptoms were treated with furosemide, a loop diuretic, and reductions in tinnitus symptoms were observed.

Abstract: Disclosed are antibiotic compositions for topical administration comprising an aminoglycoside, a benzylpyrimidine and a sulfonamide.

Abstract: There is disclosed a process for treating a warm-blooded animal wherein there is administered to the warm-blooded animal a therapeutically effective amount of composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof. The composition is useful to treat a fibrosarcoma (SAD.sub.2) tumor in warm-blooded animals.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is H, methyl, ethyl, or chloro and R.sup.2 is hydrocarbyl of 1-12 C are useful as antifungal agents. Compounds of this series wherein R.sup.2 is 7-12 C are novel. A new synthetic method for the compounds is also described.

Abstract: The invention provides physically stable anthelmintic paste compositions containing resinates of d1-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole and other anthelmintic compounds in combination with a wide variety of therapeutic agents such as antibiotics, vitamins, vaccines, or mineral supplements.

Abstract: There are described novel carboxylic acid derivatives of the formula ##STR1## and derivatives of the formula ##STR2## and the addition salts thereof, which exhibit an effect on the intermediary metabolism. Furthermore, the compounds of Formula Ia as well as the compounds of Formula I possess blood-sugar lowering properties.

Abstract: A composition adapted to prolong the residence time of sulfa and cinchona alkaloid drugs in the circulating plasma of mammals including humans comprising hexanoic acid, potassium hydrogen tartrate, tannic acid, pectin and riboflavin, with the further presence of glutamic acid in the case of sulfa drugs and L-tyrosine in the case of the cinchona alkaloids.

Abstract: There is disclosed a process for treating a warm-blooded animal to be subjected to radiotherapy or chemotherapy wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzene) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Abstract: There is disclosed a process for treating a warm-blooded animal subjected to barbituate anesthesia to potentiate effects thereof wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-3-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Abstract: There is disclosed a process for prolonging recalcification, prothrombin and thrombin times of human plasma which comprises administering to a warm-blooded animal a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Abstract: There is disclosed a process for treating a warm-blooded animal following burn injury wherein there is administered to the warm-blooded animal a therapeutically effect amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrmidine with a pharmaceutically acceptable acid and mixtures thereof.

Abstract: This invention concerns novel N-[(1H-imidazol-1-yl), (1H-1,2,4-triazol-1-yl) and (3-pyridyl)alkyl]benzenesulfonamides which are useful as inhibitors of thromboxane synthetase enzyme and/or as antihypertensive agents.